发明名称 |
Humanized Anti-HLA-DR Antibodies |
摘要 |
The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab. |
申请公布号 |
US2017066828(A1) |
申请公布日期 |
2017.03.09 |
申请号 |
US201615353141 |
申请日期 |
2016.11.16 |
申请人 |
Immunomedics, Inc. |
发明人 |
Goldenberg David M.;Hansen Hans J.;Chang Chien-Hsing |
分类号 |
C07K16/28;C07K16/42;A61K39/395;A61K47/48 |
主分类号 |
C07K16/28 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of delivering a therapeutic or diagnostic agent to an HLA-DR positive cell comprising:
a) obtaining an immunoconjugate comprising (i) a humanized anti-HLA-DR antibody or antigen-binding fragment thereof that competes for binding to HLA-DR with a murine L243 antibody comprising the heavy chain complementarity determining region (CDR) sequences CDR1 (NYGMN, SEQ ID NO: 39), CDR2 (WINTYTREPTYADDFKG, SEQ ID NO: 40), and CDR3 (DITAVVPTGFDY, SEQ ID NO: 41) and the light chain CDR sequences CDR1 (RASENIYSNLA, SEQ ID NO: 42), CDR2 (AASNLAD, SEQ ID NO: 43), and CDR3 (QHFWTTPWA, SEQ ID NO: 44), conjugated to (ii) a therapeutic or diagnostic agent; and b) exposing an HLA-DR positive cell to the immunoconjugate. |
地址 |
Morris Plains NJ US |